(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/212933 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *C07K 14/47* (2006.01)
C12N 15/11 (2006.01) *A61P 25/28* (2006.01)
A61K 31/7088 (2006.01)

(21) International Application Number:
PCT/US2025/023019

(22) International Filing Date:
03 April 2025 (03.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/574,847 04 April 2024 (04.04.2024) US

(71) Applicant: **ENCODED THERAPEUTICS, INC.** [US/US]; 341 Oyster Point Blvd., South San Francisco, California 94080 (US).


(72) Inventors: **TATAVARTY, Vedakumar**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **TAI, Chao**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **CHEN, Szu-Ying**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **RANDLES, Sawyer**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **LIU, Serena**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **DIAZ DE ARCE, Alexander Jordan**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **TAN, Steven**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **DHANOTA, Puja**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **AERAN, Rangoli**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **CHEN, Ron**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **WEBER, Alexandra**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **VALENTINE, Kristen**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US). **MAIER, Katarina**; c/o Encoded Therapeutics, Inc., 341 Oyster Point Blvd., South San Francisco, California 94080 (US).

(74) Agent: **KEDDIE, James S.**; Bozicevic, Field & Francis LLP, 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: METHODS AND COMPOSITIONS FOR REDUCING EXPRESSION OF TAU

FIG. 1



(57) Abstract: The present disclosure provides methods and compositions for the treatment of Tauopathies, including Alzheimer's Disease (AD) and Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDP-17), by inhibiting expression of the MAPT gene. Aspects of the disclosure provide engineered inhibitory RNA agents, e.g., siRNA, miRNA, and antisense oligonucleotides, that knock down endogenous mutated or wild-type MAPT transcripts in neuronal cells in a subject. Expression vectors encoding the engineered inhibitory RNA agents, e.g., in an AAV vector, are also provided.

WO 2025/212933 A1

[Continued on next page]

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*